Carisma Therapeutics Inc. CARM
0.00
0.00
NaN
as of 25 Sep
- Market cap
- $1.5M
- P/E
- 0.0×
Follow CARM
Growth Flags
show if company had growth for consecutive years
| Sep '25 | Jun '25 | Mar '25 | Dec '24 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
1.36 | — | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.20 | — | 0.65 | 0.89 | |
P/FCF ratio |
0.00 | — | 0.00 | 0.00 | |
P/Operating CF |
5.91 | — | (1.29) | (2.08) | |
P/B ratio |
0.00 | — | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | — | 0.00 | 0.00 | |
EV/Sales |
0.15 | — | 0.26 | (0.02) | |
EV/EBITDA |
0.70 | — | 0.00 | 0.01 | |
EV/Operating CF |
(0.38) | — | (0.11) | 0.01 | |
EV/FCF |
(0.39) | — | (0.11) | 0.01 | |
Quick Ratio |
0.41 | 0.22 | 0.74 | 1.12 | |
Current Ratio |
0.86 | 0.48 | 1.34 | 1.48 | |
Net Debt/EBITDA |
(0.06) | 0.35 | 0.89 | 1.04 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.07% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
2.30 | 0.00 | 0.44 | 0.33 | |
Operating CF/Net income |
0.04 | 0.60 | 1.09 | 0.47 | |
Capex/Depreciation |
0.00 | 0.00 | 0.79 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.44% | 0.00% | 245.53% | 426.44% | |
Selling, General and Administrative Expense of Revenue |
2.74% | 0.00% | 104.77% | 162.33% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.93% | 0.00% | 13.62% | 23.32% | |
Graham Net Nets |
(0.14) | — | (2.99) | (1.98) | |
Graham Number |
0.00 | — | 4.91 | 4.70 | |
Earnings Yield |
73.67% | — | (393.90%) | (347.88%) | |
Free Cash Flow Yield |
(192.58%) | — | (364.05%) | (344.83%) | |
Revenue per Share |
1.08 | 0.00 | 0.09 | 0.09 | |
Operating CF per Share |
0.05 | (0.14) | (0.24) | (0.20) | |
Capex per Share |
0.00 | 0.00 | 0.01 | 0.00 | |
Free Cash Flow per Share |
0.05 | (0.14) | (0.23) | (0.20) | |
Cash per Share |
0.07 | 0.05 | 0.19 | 0.43 | |
Shareholders Equity per Share |
(0.02) | (1.10) | (0.88) | (0.67) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.02) | (1.10) | (0.88) | (0.67) | |
Free Cash Flow |
1.91 | (5.74) | (9.54) | (8.35) | |
Working Capital |
(0.94) | (4.65) | 3.51 | 7.77 | |
Capital Expenditures |
0.00 | 0.16 | 0.52 | 0.00 | |
Net Current Asset Value |
(1.55) | (46.72) | (38.66) | (34.54) | |
EV/EBIT |
0.79 | — | 0.00 | 0.01 | |
Capex to Sales |
0.00 | 0.00 | (0.14) | 0.00 | |
Net Profit Margin |
98.82% | 0.00% | (248.48%) | (482.75%) | |
Price to Operating Income |
1.04 | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
3.65 | 3.40 | 2.71 | 3.01 | |
Average Assets |
24.31 | 32.18 | 44.87 | 60.01 | |
Average Common Equity |
(6.00) | (22.82) | (12.88) | (0.69) |
Columns are period end dates